🚀From Bench to Paper | Efficient amyloid-β degradation in Alzheimer’s disease using
#SPYTACs
Alzheimer’s disease (AD) therapy faces a key challenge: clearing pathogenic proteins efficiently while minimizing side effects.
A recent study reports SPYTACs (synthetic peptide-programmed lysosome-targeting chimeras), a fully synthetic, modular
#eTPD platform that leverages LRP1-mediated endocytosis and transcytosis to cross the Blood-Brain Barrier (
#BBB) and drive lysosomal degradation of extracellular Aβ.
In 5×FAD mice, SPYTACs reduced both peripheral and brain Aβ burden, targeted existing plaques, and improved cognitive function—with fewer inflammation and microhemorrhage risks compared to antibody-based therapies.
With high modularity, SPYTACs can be adapted to target other disease proteins (e.g.,
#Tau, PD-L1), offering a scalable and programmable strategy for neurodegeneration and beyond. Read more:
cell.com/cell/fulltext/S0092…
This study was supported by a range of high-quality reagents from MedChemExpress, including:
#Lecanemab,
#BafilomycinA1,
#Chloroquine,
#Pitstop2, DC-LC3in-D5, as well as multiple antibodies and recombinant proteins.
medchemexpress.com/
#AlzheimersDisease #Neurodegeneration #TargetedProteinDegradation #DrugDiscovery #CNS #TranslationalResearch #Biotech